<DOC>
	<DOCNO>NCT00323518</DOCNO>
	<brief_summary>CG53135-05 ( velafermin ) , recombinant human fibroblast growth factor-20 ( rhFGF-20 ) protein , investigation prevention oral mucositis . Oral mucositis commonly occur side effect high-dose chemotherapy patient undergo autologous hematopoietic stem cell transplant . The objective Phase II trial confirm safety efficacy CG53135-05 ( velafermin ) administer single dose patient risk develop oral mucositis .</brief_summary>
	<brief_title>A Phase II Controlled Trial Velafermin Prevention Oral Mucositis</brief_title>
	<detailed_description />
	<mesh_term>Mucositis</mesh_term>
	<mesh_term>Stomatitis</mesh_term>
	<criteria>Age 18 year old Patients multiple myeloma lymphoma receive myeloablative CT without TBI require autologous stem cell support . The CT regimen limit high dose melphalan ( 200 mg/m2 ) single agent , BEAM , TBI cyclophosphamide VP16 . Adequate organ function meet institutional requirement autologous stem cell transplant . A minimum CD34+ cell dose 2X106 /kg base ideal body weight ( IBW ) infuse . ECOG Performance Score 2 less Signed Informed Consent Form ( ICF ) Premenopausal female patient pregnant , lactate likely become pregnant Patients diagnose active seropositive acquire immunodeficiency syndrome ( AIDS ) Hepatitis B/ C Patients known hypersensitivity recombinant protein therapeutic Patients take velafermin ( CG5313505 ) previously Patients take palifermin past 90 day Patients take investigational drug past 30 day Patients untreated symptomatic dental infection Patients history sensitivity allergy E. coliderived product Patients WHO Grade 3 4 OM time randomization Patients sensitive allergic GCSF , Fluconazole acyclovir equivalent Patients alter mental status preclude understand informed consent process and/or completion necessary assessment Patients baseline creatinine level great equal 3 patient renal insufficiency require dialysis .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>oral mucositis</keyword>
	<keyword>hematologic</keyword>
	<keyword>autologous stem cell transplant</keyword>
	<keyword>velafermin</keyword>
	<keyword>stomatitis</keyword>
	<keyword>oncology - supportive care</keyword>
	<keyword>mouth disease</keyword>
</DOC>